A Study of Avutometinib (VS-6766) and Defactinib in People With Mesonephric Gynecologic Cancer

Abroad (travel likely)RecruitingPHASE2

Conditions

Mesonephric Gynecologic Cancer

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities), Basking Ridge, New Jersey, United States
Contact: Study coordinator (Rachel Grisham, MD) · 646-888-4653
Memorial Sloan Kettering Monmouth (Limited Protocol Activities), Middletown, New Jersey, United States
Contact: Study coordinator (Rachel Grisham, MD) · 646-888-4653
Memorial Sloan Kettering Bergen (Limited Protocol Activities), Montvale, New Jersey, United States
Contact: Study coordinator (Rachel Grisham, MD) · 646-888-4653
Memorial Sloan Kettering Suffolk -Commack (Limited Protocol Activities), Commack, New York, United States
Contact: Study coordinator (Rachel Grisham, MD) · 646-888-4653
Memorial Sloan Kettering Westchester (Limited Protocol Activities), Harrison, New York, United States
Contact: Study coordinator (Rachel Grisham, MD) · 646-888-4653
Memorial Sloan Kettering Cancer Center, New York, New York, United States
Contact: Study coordinator (Rachel Grisham, MD) · 646-888-4653
Contact: Study coordinator (Carol Aghajanian, MD) · 646-888-4217
Contact: Principal Investigator (Rachel Grisham, MD)
Memorial Sloan Kettering Nassau (Limited Protocol Activities), Uniondale, New York, United States
Contact: Study coordinator (Rachel Grisham, MD) · 646-888-4653

Study leads

Rachel Grisham, MD
Principal Investigator
Memorial Sloan Kettering Cancer Center

View source on ClinicalTrials.gov